T-Type Ca2+ channel inhibition induces p53-dependent cell growth arrest and apoptosis through activation of p38-MAPK in colon cancer cells

Molecular Cancer Research

Volumn 12, Issue 3, 2014, Pages 348-358

  Dziegielewska, Barbara ^a   Brautigan, David L ^a,b   Larner, James M ^a,b   Dziegielewski, Jaroslaw ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CALCIUM CHANNEL T TYPE; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MIBEFRADIL; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; PUMA PROTEIN; CACNA1G PROTEIN, HUMAN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CACO 2 CELL LINE; CELL CULTURE; CELL CYCLE; COLONIC NEOPLASMS; DEFICIENCY; DRUG EFFECTS; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; CACO-2 CELLS; CALCIUM CHANNELS, T-TYPE; CELL CYCLE; CELL GROWTH PROCESSES; CELLS, CULTURED; COLONIC NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897073331     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0485     Document Type: Article

References (54)

1. Clapham DE. Calcium signaling. Cell 2007;131:1047-58. (Pubitemid 350258556)
2. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287:31666-73.
3. Zhang Y, Zhang J, Jiang D, Zhang D, Qian Z, Liu C, et al. Inhibition of Ttype Ca(2+) channels by endostatin attenuates human glioblastoma cell proliferation and migration. Br J Pharmacol 2012;166:1247-60.
4. Valerie NCK, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL, et al. Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. Biochem Pharmacol 2013;85:888-97.
5. Bertolesi GE, Shi C, Elbaum L, Jollimore C, Rozenberg G, Barnes S, et al. The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 2002;62:210-9. (Pubitemid 34804099)
6. Taylor JT, Huang L, Pottle JE, Liu K, Yang Y, Zeng X, et al. Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation. Cancer Lett 2008;267:116-24.
7. Das A, Pushparaj C, Herreros J, Nager M, Vilella R, Portero M, et al. Ttype calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells. Pigment Cell Melanoma Res 2013;26:874-85.
8. Lu F, Chen H, Zhou C, Liu S,Guo M, Chen P, et al. T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium 2008;43:49-58.
9. Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol 2013;111:97-102.
10. Sheehan JP, Xu Z, Popp B, Kowalski L, Schlesinger D. Inhibition of glioblastoma and enhancement of survival via the use of mibefradil in conjunction with radiosurgery. J Neurosurg 2013;118:830-7.
11. Taylor JT, Zeng X-B, Pottle JE, Lee K, Wang AR, Yi SG, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol WJG 2008;14:4984-91.
12. Welsby PJ, Wang H, Wolfe JT, Colbran RJ, Johnson ML, Barrett PQ. A mechanism for the direct regulation of T-type calcium channels by Ca2+/calmodulin-dependent kinase II. J Neurosci Off J Soc Neurosci 2003;23:10116-21. (Pubitemid 37392559)
13. Yao J, Davies LA, Howard JD, Adney SK, Welsby PJ, Howell N, et al. Molecular basis for the modulation of native T-type Ca2+ channels in vivo by Ca2+/calmodulin-dependent protein kinase II. J Clin Invest 2006;116:2403-12. (Pubitemid 44330139)
14. Takeda K, Matsuzawa A, Nishitoh H, Tobiume K, Kishida S, Ninomiya-Tsuji J, et al. Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Rep 2004;5:161-6. (Pubitemid 38401195)
15. Liu G, Zhao J, Chang Z, Guo G. CaMKII activates ASK1 to induce apoptosis of spinal astrocytes under oxygen-glucose deprivation. Cell Mol Neurobiol 2013;33:543-9.
16. Yano S, Tokumitsu H, Soderling TR. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 1998;396:584-7. (Pubitemid 28563720)
17. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal 2004;16:1211-27. (Pubitemid 39165450)
18. Liu Z-M, Chen GG, Vlantis AC, Tse GM, Shum CKY, van Hasselt CA. Calcium-mediated activation of PI3K and p53 leads to apoptosis in thyroid carcinoma cells. Cell Mol Life Sci CMLS 2007;64:1428-36. (Pubitemid 46889237)
19. Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M. 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene 2013;32:4529-38.
20. Amorino GP, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK. Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair, leading to increased cellular radiosensitivity. J Biol Chem 2003;278:29394-9. (Pubitemid 36962318)
21. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805. (Pubitemid 39331151)
22. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83. (Pubitemid 46474662)
23. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol CB 1994;4:865-75.
24. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
25. Craig AL, Chrystal JA, Fraser JA, Sphyris N, Lin Y, Harrison BJ, et al. The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members. Mol Cell Biol 2007;27:3542-55. (Pubitemid 46685228)
26. Choi J, Park J-H, Kwon OY, Kim S, Chung JH, Lim DS, et al. T-type calcium channel trigger p21ras signaling pathway to ERK in Cav3.1-expressed HEK293 cells. Brain Res 2005;1054:22-9. (Pubitemid 41188125)
27. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
28. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838-49. (Pubitemid 38638846)
29. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999;18:6845-54.
30. Kishi H, Nakagawa K, Matsumoto M, Suga M, Ando M, Taya Y, et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001;276:39115-22.
31. Sayed M, Kim SO, Salh BS, Issinger OG, Pelech SL. Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase. J Biol Chem 2000;275:16569-73. (Pubitemid 30398881)
32. Keller DM, Lu H. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex. J Biol Chem 2002;277:50206-13. (Pubitemid 36014476)
33. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 2001;7:283-92. (Pubitemid 32206496)
34. Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A 2006;103:976-81. (Pubitemid 43212207)
35. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501. (Pubitemid 28538613)
36. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
37. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 2002;277:10824-33. (Pubitemid 34952836)
38. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
39. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo . Proc Natl Acad Sci U S A 2002;99:95-100. (Pubitemid 34060322)
40. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 2007;35:W71-74.
41. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12. (Pubitemid 351574202)
42. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, et al. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-Nmethylamino) ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 2004;309:193-9. (Pubitemid 38393130)
43. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res 1999;59:4535-41. (Pubitemid 29428953)
44. Milne DM, Palmer RH, Meek DW. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res 1992;20:5565-70.
45. Sakaguchi K, Sakamoto H, Xie D, Erickson JW, Lewis MS, Anderson CW, et al. Effect of phosphorylation on tetramerization of the tumor suppressor protein p53. J Protein Chem 1997;16:553-6. (Pubitemid 27306563)
46. Yap DBS, Hsieh J-K, Zhong S, Heath V, Gusterson B, Crook T, et al. Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 2004;64:4749-54. (Pubitemid 38924517)
47. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012;33:2007-17.
48. Cox ML, Meek DW. Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal 2010;22:564-71.
49. Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, et al. P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 2004;15:922-33. (Pubitemid 38146504)
50. Lim HW, New L, Han J, Molkentin JD. Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes. J Biol Chem 2001;276:15913-9.
51. +-dependent PP2A heterotrimer and insights into Cdc6 dephosphorylation. Cell Res 2013;23:931-46.
52. Junttila MR, Li S-P, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008;22:954-65. (Pubitemid 351519953)
53. Pottle J, Sun C, Gray L, Li M. Exploiting MCF-7 cells' calcium dependence with Interlaced Therapy. J Cancer Ther 2013;04:32-40.
54. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.